Overview

Study On Utilization Of Cabergoline For Compliance With Risk Minimization Activities (SUCRE)

Status:
Completed
Trial end date:
2013-02-01
Target enrollment:
Participant gender:
Summary
The overall goal of this study will be to assess and monitor the adherence to and effectiveness of the new prescribing guidelines for cabergoline. Specific objectives will be to assess: 1. The indication for use of cabergoline (Parkinson, hyperprolactinemia, other) 2. Prior treatment strategies in patients who start cabergoline treatment for Parkinson's Disease 3. The percentage of cabergoline users who are prescribed doses above 3 mg per day 4. Whether cabergoline users are monitored by echocardiography prior and during treatment. 5. The incidence and prevalence of valvular fibrosis
Details
Lead Sponsor:
Pfizer
Treatments:
Cabergoline